Ozdemir O
Department of Pediatrics (3(rd) Clinic), Allergy-Immunology Division, İstanbul Göztepe Research and Training Hospital, Göztepe, Kadıköy, Türkiye. ozdemir
Allergol Immunopathol (Madr). 2011 Sep-Oct;39(5):259-66. doi: 10.1016/j.aller.2010.07.007. Epub 2011 Jan 13.
Chromium release assay is the standard method for evaluation of cell-mediated cytotoxicity, including that of mast cells. Although this is a reproducible method, it has more drawbacks than even radioactivity. In addition to the shortcoming of measuring only necrotic killing, some non-radioactive methods have not been widely used either. The numerous limitations of these methods led researchers to develop other techniques. This study describes a new flow cytometric approach that measures human mast cell-mediated cytotoxicity by marking target cells with monoclonal antibody alongside annexin V/ PI co-labelling.
A colony forming unit - mast in vitro was developed from human bone marrow mononuclear cells in serum-free methylcellulose medium. Six-week-old human bone marrow-derived mast cells were used as effectors, and malignant B-lymphoblastoid cell lines like Daudi / Raji cells as targets. Effectors and targets were both co-incubated for short and long-term durations, and experiments were repeated several times. Cytotoxicity was calculated by flow cytometric mast cell-mediated cytotoxicity assay.
This method was able to clearly show mast cell-mediated cytotoxicity against human tumours. It is well-known that some lymphokine-activated killer-sensitive cells are resistant to mast cell-mediated cytotoxicity. However, a different type of lymphokine activated killer-sensitive cell in this study was found to be very sensitive to mast cell-mediated cytotoxicity. Moreover, this technique also allowed us to separate killing into different stages: early and late apoptosis.
When compared to chromium release and non-radioactive methods, this method has the advantages of allowing evaluation of early apoptosis and short/long term mast cell-mediated cytotoxicity with specific target marking.
铬释放试验是评估细胞介导的细胞毒性的标准方法,包括肥大细胞的细胞毒性。尽管这是一种可重复的方法,但它的缺点甚至比放射性方法还多。除了仅测量坏死性杀伤的缺点外,一些非放射性方法也未得到广泛应用。这些方法的众多局限性促使研究人员开发其他技术。本研究描述了一种新的流式细胞术方法,该方法通过用单克隆抗体标记靶细胞并结合膜联蛋白V/碘化丙啶(PI)共标记来测量人肥大细胞介导的细胞毒性。
在无血清甲基纤维素培养基中,从人骨髓单个核细胞中培养出体外肥大细胞集落形成单位。六周龄的人骨髓来源的肥大细胞用作效应细胞,恶性B淋巴细胞样细胞系如Daudi/Raji细胞用作靶细胞。效应细胞和靶细胞进行短期和长期共孵育,实验重复多次。通过流式细胞术肥大细胞介导的细胞毒性试验计算细胞毒性。
该方法能够清晰地显示肥大细胞对人肿瘤的细胞毒性。众所周知,一些淋巴因子激活的杀伤敏感细胞对肥大细胞介导的细胞毒性具有抗性。然而,本研究中发现一种不同类型的淋巴因子激活的杀伤敏感细胞对肥大细胞介导的细胞毒性非常敏感。此外,该技术还使我们能够将杀伤分为不同阶段:早期和晚期凋亡。
与铬释放法和非放射性方法相比,该方法具有能够评估早期凋亡以及通过特异性靶细胞标记评估短期/长期肥大细胞介导的细胞毒性的优点。